CureVac
Alexander Zehnder, MD, MBA, currently serves as the Chief Executive Officer of CureVac since April 2023. Prior to this role, Alexander Zehnder held multiple leadership positions at Sanofi Genzyme from October 2014 to February 2023, including Global Head Oncology, as well as President & Managing Director for Italy and Malta. Alexander Zehnder’s experience at Roche spanned from January 2004 to September 2014, notably as General Manager for Roche Greece and Cyprus, VP of Global Product Strategy and Global Franchise Head for Avastin, and Global Lifecycle Leader for Avastin. Academic qualifications include a Doctor of Medicine (M.D.) from the University of Bern and a Master of Business Administration (MBA) from IMD.
This person is not in any teams
CureVac
7 followers
CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and optimizing the versatile biological molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of non-chemically modified mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases.